Delex Through the Years

The pioneer, led by a regulatory pharmacist and supported by two sales forces, conquered the arena of the pharmaceutical industry on JULY 13, 2009. The year was a breakthrough in DPII to operate with its mother company, which is one of the fastest-growing distribution companies in the country, namely Globo Asiatico Enterprises, Inc.

The first two main products which were instrumental to DPII’s success, both promoted in GMA and Luzon, were Buminate (Albumin 25%) of Baxter-Bioscience and Tramadol (Milador) Inj. of Sandoz Philippines. These two distributors are among the most recognized pharmaceutical production companies worldwide.

The company signed a Distribution and Marketing Agreement with leading international pharmaceutical companies from South East Asia, South Asia, and even from the US. These are United Biotech (India), ICU Medical Inc. (USA), and Innogene Kalbiotech, now Kalbe (Indonesia).

Delex Pharma International Inc. expanded its team from three (3) to nineteen (19) accomplished employees in 2010 as it continues to excel in the industry

Although DPII was new, it did not hinder the company from having another impressive milestone. It engaged in Marketing Agreements with well-known national and multinational companies.

Since the company provided a caliber performance, Astellas Pharma of Tokyo, Japan invested in the distribution of its original Nicardipine, Perdipine products. With the tactical marketing of DPII, these products had overtaken the spotlight of Unilab’s Cardepine brand.

Before the closure of Baxter Commercial in the Philippines in 2013, it entrusted DPII to market its critical care products, namely Flexbumin (Human Albumin), Premixed Potassium Chloride, and Premixed Dopamine. These products were introduced successfully to their niche market with the expertise of Delex Pharma International Incorporated.

This year was a fruitful one for the company as it also became an instrument to help Janssen Pharmaceutical to promote Sublimaze, the innovator brand of Fentanyl Citrate. Unluckily, Janssen was amidst a setback during this year that affected market share. But with DPII’s extensive experience in marketing, it triumphantly regained its thriving direction after two years of marketing the product.

Proudly in the same year, the company had again showcased its proven potential in contributing success to its partners. DPII had signed an alliance with Innogene Kalbiotech. Back in 2007, Innogene Kalbiotech’s TotilacTM (Hypertonic Lactate) was not promoted profitably with a sales volume of 37 bags for two years. However, DPII tremendously reaped victory as it sold 5,500 bags in its first year of strategically marketing the brand in 2010

Undoubtedly, the success of the company for the past two years brought another deserving event as they introduced their product lines in 2011. These were Norepinephrine, Norepin, in three (3) SKUs, 2ml, 4ml & 10ml, and Dobutamine brand (Dobulex). Moreover, Norepin is among the most trusted generic norepinephrine brands in the Philippine market.

The company’s force, which was shaped by professionals, had built-up reliability and confidence in supplying quality critical care products to hospitals, and business partners nationwide. Hence, this had led DPII from continuously holding its reputable name higher.

In 2012, DPII recommences what unfolded in the beginning, as it signed a Distribution Agreement with MD Pharma, which is known for providing various quality pharmaceutical products. The partnership aimed to launch products and establish a new Division -- Primary Care. The company had also organized a Trade Sales Division to further reinforce its nationwide services in hospitals and drugstore accounts.

Customer relations is in the heart of Delex Pharma International Inc. Thus, DPII made sure that they can independently maneuver the distribution services to refine access to different channels. This calculated method had directly served the satisfaction of clients and ensured that the products were promptly available, especially in critical times. Additionally, the company had boosted its business operations by adopting ?SAP applications. It allowed DPII to track business processes and transactions in the most organized manner.

With a greater purpose, DLX Holdings and High Everest Capital, Inc. acquired DPII from its mother company, Globo Asiatico. It was also the year where DPII moved to a new office in 189 Mindanao Avenue, Barangay Bahay Toro, Quezon City.

In 2013, the company sustained the momentum of skyrocketing in the field as it ventured into the anti-infective business. It launched its first two antibiotic products, Ceftazin (Ceftazidime) and Ceftrex (Ceftriaxone) manufactured by United Biotech, India.

DPII continued to broaden its horizon and applied a concept-selling marketing strategy as it initiated the promotion of Ifimol IV (Paracetamol) in 1g vial (premixed, water-based) aimed to transition from ampoule usage.

The company did not stop in extending its ability in product line distributions to aggregate its Anesthesia/Analgesia portfolio. It kicked off the marketing of Lexofol (Propofol) from Ambica Pharmaceuticals. Lexofol is one of the few Propofol brands in the market available in vial preparation.

Part of the company’s persistence in delivering notable accomplishments is the engagement of home-grown managers in enhancing their communication and leadership skills by partnering with Toastmasters International. It is a non-profit organization that teaches public speaking and leadership skills across a worldwide network of clubs.

Along its way, DPII had incorporated the Total Quality Management (TQM) Program. It aims to align the employees to be committed to maintaining high standards of work in every aspect of the company's internal policies and operations.

In 2014, DPII widened its partnerships to several companies, which proved the company’s potential in breaking through the pharmaceutical industry.

It had steadily augmented its business line and acquired dispensation of Midazolex to provide Anesthesiologists an alternative Midazolam I.V./I.M. The product is from Myungmoon Pharm, Korea.

The company had also debuted the supply of TEGO, which is the first and only needle-free connector US FDA-approved for use in hemodialysis to augment the device business. Also, it initiated the next wave launch of antibiotic products, namely Spectrax (Cefipime) and Bacimycin (Clindamycin). The antibiotic products are acquired from Claris Lifesciences, which is a company dealing in Specialty Injectable business. Sandoz Philippines Corporation had as well came to an agreement with DPII to market their generic brand of Fentanyl patch (Fendermal).

The company had again expanded its distribution channel as a corporate liaison to the biggest drugstore chain in the country, Mercury Drug Corporation.

In the same year, Delex Pharma International Inc. had an arrangement with PWC as an external auditor. It is designated to further build structure and control in the company’s finances based on international standards.

Along with empowering its employees, the organization had willingly embraced Corporate Social Responsibility. It sponsored the education of fifty (50) indigent children. This program is in partnership with World Vision, a global humanitarian organization dedicated to improving people’s lives to overcome poverty.

The institution increased its number of competent employees, along with its growing business. In 2015, Delex Pharma purchased a 360-square meter property in Brgy. Sauyo, Quezon City, as the new home of its workforce.

Furthermore, DPII wanted to raise its standards beyond excellence and to envision leadership among its employees. Thus, it established the Delex University and formed a partnership with San Beda College for an on-site MBA program. Consequently, the firm ranked 42nd in the top 100 corporations based on hospital index reports by IMS.

The company had equally strengthened its IT infrastructure, as it is beneficial to respond to the growing need of the company for an enhanced information management system.

The success of the organization from the previous years had brought another partnership done with Smiths Medical, a leading global manufacturer of specialty medical devices. Delex Pharma had promoted ambulatory infusion pumps (CADD Legacy PCA & its consumables) to supplement the hospital device business. More so, DPII allied with RBC distribution company to focus efforts in marketing, inventory optimization, and in-housing its product lines and own brands.

In 2016, the Marketing Department instituted the ICU Forum Program for Medical Doctors that signifies the company’s commitment to providing Continuing Medical Education (CME) support to Health Care providers. The company also founded the Spiritual Holistic Integrated Empowered Leaders of Delex (SHIELD) program, which is led by its Director, Fr. Gil Peter Coching. The program is for acculturation and values formation that empowers relevant skills and spiritual values among the young workforce.

Delex Pharma primarily focused on marketing advanced businesses in Critical Care, Anesthesia/Analgesia, and Medical Device. Then sooner, it gained a jumpstart in housing all the brands that they have been promoting only for the past six years while besting the challenges.

In the same year, DPII confidently handled its product distribution. It aimed to develop well-maintained customer reach and service to deliver satisfaction.

Meanwhile, the fifty (50) indigent scholars, which were responsibly shouldered by DPII, increased to eighty (80) students.

2017 was a blast for DPII after receiving various awards, which were the consequences of the brilliant steps they have endeavored. The organization received awards from Asia CEO – Executive Leadership Team of the Year and SME Company of the Year. With the attested impact to its partners, the company placed fifth (5th) in the hospital sector based on an IQVIA report.

This year was another milestone for the organization, when it established two more banner brands -- Norepin (norepinephrine) and Ifimol (Paracetamol I.V). Concurrently, it launched Nicardilex (Nicardipine) & Funginil (Fluconazole) to go with the Critical Care Franchise.

Furthermore, the powerhouse of Delex Pharma grew to one hundred eighty (180) adept and experienced employees to serve its expanding network.

Meanwhile, DPII rented a 425 square meter property in Valenzuela to house its products and its delivery operations.

Digital modification is advancing in all aspects of the business, and the workforce is no exception. With this, DPII rode along with the technological advancement providing an iPad to the sales force, which enhanced the implementation of Sales Force Effectiveness or SFE. Moreover, the firm allied with E-science for pocket wise systems application to improve customer reach.

In 2018, Delex Pharma continued to a headway as it initiated the innovator brand Ibuprofen I.V., Intrafen, and the first branded generic Linezolid, Axazolid. Moving closer to a decade of outwitting challenges, it established an affiliate company (JMN Bothers) which focuses on the non-ICU market. It was also the period when it was certified by PRC as a Continuing Professional Development or CPD provider.

The organization never ceased in hastening the skills of its employees. DPII launched a Master Class Program of Delex University to provide Leadership and Marketing training for Middle and Senior Managers. It is under the coaching of Prof. Dominador “Ringo” Gamboa from San Beda Graduate School. More so, the implementation of the first ICU Forum for pharmacists took place.

Along with the efforts made this year is the institutionalization of its Corporate Social Responsibility or CSR Programs. Also, the original fifty (50) indigent scholars the company has been supporting ballooned to one hundred (100).

Meanwhile, it also expanded its warehouse facility in Valenzuela and rented another property with a 665 square meter lot area.

Delex Pharma International, Inc. persistently scaled up its performance and network until it reached its significant tenth (10th) anniversary in 2019!

DPII continued with its program in nurturing the Health Care Providers in the country. It implemented the first Joint ICU Forum for Nurses and Pharmacists in collaboration with Critical Care Medicine of the Philippine Heart Center. Moreover, it increased the number of ICU Forum Faculty as a backbone to strengthen its goal.

Continuous learning is embedded in the heart of the organization to cope up with the fast-evolving environment and rapid advancement of businesses. In line with this, it launched a Mandarin Class for Management Teams to support the vision of future business expansion. It also partnered with Life Enhancement Consultancy to advance the HR program for Organizational Development and to reinforce marketing initiatives.

While technology delivers accuracy in a lot of aspects, DPII launched Mobile Dosage Calculator App for Norepin (Norepinephrine), Dobulex (Dobutamine), and Nicardilex (Nicardipine Hydrochloride). The app is downloadable from the ICU Forum website.

It was also during this notable year when CMO Asia recognized Delex Pharma International Inc. DPII took home the PHILIPPINES BEST BRAND Award 2019. Likewise, the VP for Marketing, Ms. Lourdes Monasterio, proudly received the PHILIPPINES WOMEN LEADERS Award 2019.